Newman L (2001) IOM Report sets policy priorities for improving breast cancer screening. J Natl Cancer Inst 93(8):574–575 ArticleCASPubMed Google Scholar
Ritchie CS, Kvale E, Fisch MJ (2011) Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 7(6):371–374 ArticlePubMed CentralPubMed Google Scholar
Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34):8606–8612 ArticlePubMed Google Scholar
Undela K, Srikanth V, Bansal D (2012) Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 135(1):261–269 ArticleCASPubMed Google Scholar
Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29(9):585–593 ArticleCASPubMed Google Scholar
Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461–1468 ArticleCASPubMed CentralPubMed Google Scholar
Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573–579 ArticleCASPubMed CentralPubMed Google Scholar
Grossman E, Messerli FH, Goldbourt U (2002) Carcinogenicity of antihypertensive therapy. Curr Hypertens Rep 4(3):195–201 ArticlePubMed Google Scholar
Felmeden DC, Lip GY (2001) Antihypertensive therapy and cancer risk. Drug Saf 24(10):727–739 ArticleCASPubMed Google Scholar
Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628–638 PubMed CentralPubMed Google Scholar
Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 29(19):2635–2644 ArticleCASPubMed Google Scholar
Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129(2):549–556 ArticleCASPubMed CentralPubMed Google Scholar
Nickels S, Vrieling A, Seibold P, Heinz J, Obi N, Flesch-Janys D, Chang-Claude J (2013) Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS ONE 8(9):e75088 ArticleCASPubMed CentralPubMed Google Scholar
Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor M (2013) Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 4(7):549–556 ArticlePubMed CentralPubMed Google Scholar
Sorensen GV, Ganz PA, Cole SW, Pedersen LA, Sorensen HT, Cronin-Fenton DP, Garne JP, Christiansen PM, Lash TL, Ahern TP (2013) Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers, and risk of breast cancer recurrence: a danish nationwide prospective cohort study. J Clin Oncol 31(18):2265–2272 ArticlePubMed Google Scholar
McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI (2013) Long-term statin use and risk of ductal and lobular breast cancer among women 55–74 years of age. Cancer Epidemiol Biomarkers Prev 22(9):1529–1537 ArticlePubMed Google Scholar
Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE (2013) Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Int Med 173(17):1629–1637 Article Google Scholar
Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16(4):508–519 ArticleCASPubMed Google Scholar
Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10–19 CASPubMed Google Scholar
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(12):930–942 ArticleCASPubMed Google Scholar
Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22(8):1139–1148 ArticleCASPubMed Google Scholar
Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H (2001) Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 61(12):4885–4891 CASPubMed Google Scholar
Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ (2001) Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 7(7):2067–2075 CASPubMed Google Scholar
Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V et al (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342(6162):1094–1098 ArticleCASPubMed Google Scholar
Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P (1990) Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 8(6):565–572 ArticleCASPubMed Google Scholar
Rosenthal T, Gavras I (2009) Angiotensin inhibition and malignancies: a review. J Hum Hypertens 23(10):623–635 ArticleCASPubMed Google Scholar
Molteni A, Ward WF, Ts’ao CH, Taylor J, Small W Jr, Brizio-Molteni L, Veno PA (2003) Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des 9(9):751–761 ArticleCASPubMed Google Scholar
Fitzgerald PJ (2010) Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin Epidemiol 2:1–3 PubMed CentralPubMed Google Scholar
Fitzgerald PJ (2009) Is norepinephrine an etiological factor in some types of cancer? Int J Cancer 124(2):257–263 ArticleCASPubMed Google Scholar
Drell TLt, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63–70 ArticleCASPubMed Google Scholar
Lang K, Drell TLt, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112(2):231–238 ArticleCASPubMed Google Scholar
Masur K, Niggemann B, Zanker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61(7):2866–2869 CASPubMed Google Scholar
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L et al (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042–7052 ArticleCASPubMed CentralPubMed Google Scholar
Daling JR (1996) Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 9(7):713–714 ArticleCASPubMed Google Scholar
Howes LG, Edwards CT (1998) Calcium antagonists and cancer. Is there really a link? Drug Saf 18(1):1–7 ArticleCASPubMed Google Scholar
Mason RP (1999) Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer 85(10):2093–2102 ArticleCASPubMed Google Scholar
Sarafidis PA, McFarlane SI, Bakris GL (2007) Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr DiabRep 7(3):191–199 ArticleCAS Google Scholar
ALLHAT, Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288(23):2998–3007 Google Scholar
Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6(2):103–111 ArticleCASPubMed Google Scholar
Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM (2013) Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev 22(9):1588–1599 ArticlePubMed Google Scholar
Calip GS, Boudreau DM, Loggers ET (2013) Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat 138(1):225–233 ArticleCASPubMed CentralPubMed Google Scholar
Greene FL (2002) The American Joint Committee on Cancer: updating the strategies in cancer staging. Bulletin of the American College of Surgeons 87(7):13–15 PubMed Google Scholar
Buist DS, Ichikawa L, Prout MN, Yood MU, Field TS, Owusu C, Geiger AM, Quinn VP, Wei F, Silliman RA (2007) Receipt of appropriate primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women with access to health care. J Clin Oncol 25(23):3428–3436 ArticlePubMed Google Scholar
Enger SM, Thwin SS, Buist DS, Field T, Frost F, Geiger AM, Lash TL, Prout M, Yood MU, Wei F et al (2006) Breast cancer treatment of older women in integrated health care settings. J Clin Oncol 24(27):4377–4383 ArticlePubMed CentralPubMed Google Scholar
Geiger AM, Thwin SS, Lash TL, Buist DS, Prout MN, Wei F, Field TS, Ulcickas Yood M, Frost FJ, Enger SM et al (2007) Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer 109(5):966–974 Google Scholar
Saunders KW, Davis RL, Stergachis A (2005) Group Health Cooperative. In: Strom BL (ed) Pharmacoepidemiolog_y_, 4th edn. Wiley, West Sussex, pp 223–239 Google Scholar
Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7–8):1317–1318 ArticlePubMed Google Scholar
Buist DS, LaCroix AZ, Brenneman SK, Abbott T (2004) A population-based osteoporosis screening program: who does not participate, and what are the consequences? J Am Geriatr Soc 52(7):1130–1137 ArticlePubMed Google Scholar
Thwin SS, Clough-Gorr KM, McCarty MC, Lash TL, Alford SH, Buist DS, Enger SM, Field TS, Frost F, Wei F et al (2007) Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol 7:23 ArticlePubMed CentralPubMed Google Scholar
McKenney JM (2003) Pharmacologic characteristics of statins. Clin Cardiol 26(4 Suppl 3):III32–III38 Google Scholar
Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW et al (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274(8):620–625 ArticleCASPubMed Google Scholar
Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127–2132 ArticlePubMed Google Scholar
Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C (2010) Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48(6 Suppl):S96–S105 ArticlePubMed Google Scholar
Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619 ArticleCASPubMed Google Scholar
Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C (1999) The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 52(3):199–207 ArticleCASPubMed Google Scholar
Boudreau DM, Malone DC, Raebel MA, Fishman PA, Nichols GA, Feldstein AC, Boscoe AN, Ben-Joseph RH, Magid DJ, Okamoto LJ (2009) Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord 7(4):305–314 ArticleCASPubMed Google Scholar
Malone DC, Boudreau DM, Nichols GA, Raebel MA, Fishman PA, Feldstein AC, Ben-Joseph RH, Okamoto LJ, Boscoe AN, Magid DJ (2009) Association of cardiometabolic risk factors and prevalent cardiovascular events. Metab Syndr Relat Disord 7(6):585–593 ArticlePubMed Google Scholar
U.S. Census Bureau (2011) Statistical abstract of the United States: 2012, 131st edn. Washington, DC
Holmes MD, Hankinson SE, Feskanich D, Chen WY (2013) Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 139(2):507–513 ArticleCASPubMed Google Scholar
George AJ, Thomas WG, Hannan RD (2010) The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10(11):745–759 ArticleCASPubMed Google Scholar
Phipps AI, Ichikawa L, Bowles EJ, Carney PA, Kerlikowske K, Miglioretti DL, Buist DS (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60–66 ArticlePubMed CentralPubMed Google Scholar